Progyny (PGNY) Expected to Announce Quarterly Earnings on Thursday

Progyny (NASDAQ:PGNY) will likely be announcing its Q2 2025 earnings results after the market closes on Thursday, August 7th. Analysts expect the company to announce earnings of $0.42 per share and revenue of $315.70 million for the quarter. Progyny has set its Q2 2025 guidance at 0.400-0.430 EPS and its FY 2025 guidance at 1.540-1.640 EPS.

Progyny (NASDAQ:PGNY) last issued its quarterly earnings data on Thursday, May 8th. The company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.45 by ($0.28). Progyny had a return on equity of 10.90% and a net margin of 4.33%. The company had revenue of $324.04 million for the quarter, compared to the consensus estimate of $307.86 million. During the same period in the prior year, the company earned $0.17 EPS. The firm’s revenue was up 16.5% on a year-over-year basis. On average, analysts expect Progyny to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Progyny Stock Up 2.9%

Shares of PGNY stock opened at $23.50 on Thursday. The firm has a fifty day moving average of $22.02 and a 200-day moving average of $22.06. Progyny has a 12-month low of $13.39 and a 12-month high of $28.99. The company has a market capitalization of $2.01 billion, a price-to-earnings ratio of 41.23, a P/E/G ratio of 2.29 and a beta of 1.31.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on PGNY shares. Leerink Partnrs raised shares of Progyny from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 8th. Leerink Partners raised shares of Progyny from a “market perform” rating to an “outperform” rating and set a $28.00 price objective for the company in a research report on Tuesday, July 8th. Wall Street Zen raised shares of Progyny from a “hold” rating to a “buy” rating in a research report on Saturday, July 26th. Canaccord Genuity Group reduced their target price on shares of Progyny from $23.00 to $21.00 and set a “hold” rating for the company in a report on Monday, May 12th. Finally, Truist Financial set a $27.00 target price on shares of Progyny and gave the stock a “hold” rating in a report on Thursday, July 17th. Five research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Progyny has a consensus rating of “Moderate Buy” and a consensus target price of $24.82.

Insider Activity at Progyny

In other news, Director Cheryl Scott sold 2,675 shares of Progyny stock in a transaction dated Wednesday, June 11th. The shares were sold at an average price of $22.07, for a total value of $59,037.25. Following the completion of the transaction, the director owned 14,112 shares of the company’s stock, valued at $311,451.84. This trade represents a 15.93% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 9.40% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Amundi lifted its stake in shares of Progyny by 103.8% during the 1st quarter. Amundi now owns 11,419 shares of the company’s stock worth $264,000 after buying an additional 5,817 shares during the last quarter. Royal Bank of Canada lifted its stake in shares of Progyny by 384.8% during the 1st quarter. Royal Bank of Canada now owns 13,027 shares of the company’s stock worth $291,000 after buying an additional 10,340 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Progyny by 6.0% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 252,032 shares of the company’s stock worth $5,630,000 after buying an additional 14,297 shares during the last quarter. Institutional investors own 94.93% of the company’s stock.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.